The following is a summary of “Evaluating Surgical Outcomes of Robot Assisted Simple Prostatectomy in the Retreatment Setting,” published in the December 2022 issue of Urology by Garbens, et al.

For a study, researchers sought to evaluate the perioperative and postoperative results between men getting salvage RASP (sRASP) after another endoscopic outlet surgery for benign prostate enlargement (BPE) and those undergoing RASP as their primary form of therapy (pRASP).

A prospectively kept database was utilized to compile information on all RASP operations (December 2014–October 2019) carried out at the facility by three different urologists. Prior to their RASP, patients who had undergone an endoscopic treatment for BPE (sRASP) were compared to those who hadn’t undergone any prior outlet surgery (pRASP).

Over the course of the investigation, 310 males underwent RASP. Thirty of them (9.7%) had had an endoscopic treatment before the operation. Age, race, ASA, BMI, prostate volume, PSA, or preoperative retention rates did not differ significantly from one another (P >.05 for all). Preoperative International Prostate Symptom Scores (IPSS) were considerably higher in men who had never had therapy (18.3 ± 7.7 vs 13.6 ± 6.2, P = .008) than in individuals who had undergone a previous surgery. Between the two groups, there were no appreciable changes in function or quality of life outcomes (P >.05 for all). The two groups’ perioperative and postoperative results did not differ significantly. Additionally, the incidence of incontinence (2% vs 0%, P = 1) and postoperative complications (11% vs 10%, P =.9) were comparable between groups.

An endoscopic technique for BPE followed by a RASP was proven to be both safe and effective. The success and complication rates were comparable to those of people who had never had surgery.